1. Home
  2. HEPA vs UK Comparison

HEPA vs UK Comparison

Compare HEPA & UK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HEPA
  • UK
  • Stock Information
  • Founded
  • HEPA 2013
  • UK 2015
  • Country
  • HEPA United States
  • UK China
  • Employees
  • HEPA N/A
  • UK N/A
  • Industry
  • HEPA Biotechnology: Pharmaceutical Preparations
  • UK Business Services
  • Sector
  • HEPA Health Care
  • UK Consumer Discretionary
  • Exchange
  • HEPA Nasdaq
  • UK Nasdaq
  • Market Cap
  • HEPA 1.7M
  • UK 1.6M
  • IPO Year
  • HEPA N/A
  • UK N/A
  • Fundamental
  • Price
  • HEPA $0.17
  • UK $1.18
  • Analyst Decision
  • HEPA
  • UK
  • Analyst Count
  • HEPA 0
  • UK 0
  • Target Price
  • HEPA N/A
  • UK N/A
  • AVG Volume (30 Days)
  • HEPA 31.4M
  • UK 86.7K
  • Earning Date
  • HEPA 04-15-2025
  • UK 03-15-2025
  • Dividend Yield
  • HEPA N/A
  • UK N/A
  • EPS Growth
  • HEPA N/A
  • UK N/A
  • EPS
  • HEPA N/A
  • UK N/A
  • Revenue
  • HEPA N/A
  • UK $42,470,655.00
  • Revenue This Year
  • HEPA N/A
  • UK N/A
  • Revenue Next Year
  • HEPA N/A
  • UK N/A
  • P/E Ratio
  • HEPA N/A
  • UK N/A
  • Revenue Growth
  • HEPA N/A
  • UK N/A
  • 52 Week Low
  • HEPA $0.12
  • UK $1.04
  • 52 Week High
  • HEPA $3.33
  • UK $3.70
  • Technical
  • Relative Strength Index (RSI)
  • HEPA 36.41
  • UK 52.03
  • Support Level
  • HEPA $0.17
  • UK $1.11
  • Resistance Level
  • HEPA $0.19
  • UK $1.21
  • Average True Range (ATR)
  • HEPA 0.02
  • UK 0.07
  • MACD
  • HEPA 0.01
  • UK 0.00
  • Stochastic Oscillator
  • HEPA 28.55
  • UK 45.92

About HEPA Hepion Pharmaceuticals Inc.

Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.

About UK Ucommune International Ltd

Ucommune International Ltd is a flexible office space provider and manager based in the People's Republic of China (PRC). The company offers long-term leasing, on-demand, and short-term leasing solutions to freelancers, start-up entrepreneurs, small and medium enterprises, and corporations. They provide fully-serviced and well-furnished office spaces on a flexible basis. The members of the Ucommune community, which includes individuals and enterprises registered on the U bazaar mobile app, can avail of these services. The company has three operating segments: Workspace membership, Marketing and branding services, and Other services. Marketing and branding services generate the majority of the company's revenue.

Share on Social Networks: